Base de données de lignes directrices sur le cancer

Vous pouvez consulter des lignes directrices de qualité sur le cancer à partir d’une seule source canadienne.

Voici une liste de 45 lignes directrices sous le(s) thème(s)"Types de cancer". Les plus récentes sont en premier.

Bone Cancer, Version 1.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with bone cancer. The guideline focuses on chordoma, chondrosarcoma, Ewing sarcoma, osteosarcoma, and provides recommendations for treating giant cell tumour of the bone (GCTB). Workup, treatment, surveillance, and relapsed disease are discussed for each of the types of bone cancer mentioned. Staging, high-grade undifferentiated pleomorphic sarcoma of bone, and immunotherapy for bone cancer are also considered.

Recommendations for Filgrastim Use in Adults by Disease Site

Year: 2018
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for adult oncology patients with neutropenia. The guideline examines the appropriate prescribing of filgrastim for these patients. Indications for which filgrastim should be used are discussed by disease site group. Disease site groups considered include breast, central nervous system, gastrointestinal, gynecologic, genitourinary, hematologic, and thoracic, amongst others.

AIDS-Related Kaposi Sarcoma, Version 2.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with AIDS-related Kaposi sarcoma. The guideline examines diagnosis, staging, treatment, and follow-up, while also providing recommendations on HIV screening and HIV therapy during cancer treatment. Antiretroviral therapy (ART), topical therapies, intralesional chemotherapy, local incisions, radiation therapy, and systemic therapy are all discussed as treatment options.

Bone Cancer, Version 2.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with primary bone cancer. The guideline examines systemic therapy agents and radiation therapy for chordoma, chondrosarcoma, Ewing sarcoma, osteosarcoma, and giant-cell tumours of bone (GCTB). The guideline also discusses the management of relapsed disease.

Myelodysplastic Syndromes, Version 2.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with myelodysplastic syndromes (MDS). The guideline discusses diagnostic classification, evaluation, prognostic stratification, therapeutic options, and recommended treatment approaches for MDS. There is a particular focus on supportive care, and the guideline also provides recommendations for the management of thrombocytopenia and iron overload, the treatment of related anemia, the use of low-intensity therapy (i.e. hypomethylating agents or biologic response modifiers and immunosuppressive therapy), and high-intensity therapy.

Soft Tissue Sarcoma, Version 2.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of soft tissue sarcoma (STS) in adult patients. The guideline pertains to the following five subtypes of STS: (1) STS of extremity, superficial/trunk, or head and neck, (2) retroperitoneal or intra-abdominal STS, (3) gastrointestinal stromal tumours (GISTs), (4) desmoid tumours, and (5) rhabdomyosarcoma (RMS). The guideline provides recommendations for diagnosis, staging, treatment, palliative care, and surveillance. Surgery, chemotherapy, and radiotherapy are all examined as treatment options.

Myelodysplastic Syndromes, Version 2.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with myelodysplastic syndromes (MDS). The guideline discusses diagnostic classification, evaluation, prognostic stratification, therapeutic options, and recommended treatment approaches for MDS. There is a particular focus on supportive care, and the guideline also provides recommendations for the management of thrombocytopenia and iron overload, the treatment of related anemia, the use of low-intensity therapy (i.e. hypomethylating agents or biologic response modifiers and immunosuppressive therapy), and high-intensity therapy.

Soft Tissue Sarcoma, Version 1.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of soft tissue sarcoma (STS) in adult patients. The guideline pertains to the following five subtypes of STS: (1) STS of extremity, superficial/trunk, or head and neck, (2) retroperitoneal or intra-abdominal STS, (3) gastrointestinal stromal tumours (GISTs), (4) desmoid tumours, and (5) rhabdomyosarcoma (RMS). The guideline provides recommendations for diagnosis, staging, treatment, palliative care, and surveillance. Surgery, chemotherapy, and radiotherapy are all examined as treatment options.

Soft-Tissue Sarcoma: Management of Metastatic Disease

Year: 2017
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adult patients with soft-tissue sarcoma who are being considered for chemotherapy. The guideline provides recommendations for staging procedures and classifications, as well as treatment options based on staging results and other risk factors. Treatment options including surgery, systemic therapy, radiation therapy, and chemotherapy are discussed. Outcomes of interest include adverse events, performance status, progression-free survival, and overall survival.

AIDS-Related Kaposi Sarcoma, Version 1.2018

Year: 2017
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with AIDS-related Kaposi sarcoma. The guideline examines diagnosis, staging, treatment, and follow-up, while also providing recommendations on HIV screening and HIV therapy during cancer treatment. Antiretroviral therapy (ART), topical therapies, intralesional chemotherapy, local incisions, radiation therapy, and systemic therapy are all discussed as treatment options.

Clinical Practice Guidelines for the Management of Adult Onset Sarcoma

Year: 2016
AGREE II score: Disponible
Developer organization: Cancer Council Australia
A clinical practice guideline for the management of adult onset sarcoma. The guideline examines the diagnosis, staging, treatment, and follow-up options for sarcoma. Imaging modalities for the purpose of diagnosis and staging are compared, while the importance of multidisciplinary care and the effects of delayed referrals to specialists are discussed. In addition, pre-operative and post-operative radiotherapy are compared, and the guideline also examines adjuvant and systemic chemotherapy, as well as surgical procedures. This guideline is wiki-based and is constantly updated as new evidence arises - this review pertains to the guideline as of April 23, 2018.

Palliative Radiotherapy: Bone Metastases and Spinal Cord Compression

Year: 2016
AGREE II score: Disponible
Developer organization: Alberta Health Services
A clinical practice guideline for patients with bone metastases and spinal compression as common causes of cancer-related pain. The guideline examines radiotherapy and prophylactic steroids to reduce pain and pain flares. Outcomes of interest include improved neurological outcomes, survival, and reduced functional interference.

Bone Cancer – Version 1.2017

Year: 2016
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline reviews workup and treatment of bone cancer, with specific recommendations provided for chondrosarcoma, chordoma, Ewing's sarcoma family of tumors, and osteosarcoma. Surveillance and relapse is also reviewed. An overview of systemic therapy agents is provided, and principles of radiation therapy are discussed.

Recommendations for Filgrastim Use in Adults by Disease Site

Year: 2016
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline to guide appropriate prescribing of filgrastim in adults. The guidelines looks at a variety of disease sites and is intended as a guide to facilitate a shared approach to the appropriate use of filgrastim. In order provide clarity surrounding the indications in which filgrastim should be used, the recommendations are presented by disease site.

Tobacco Screening and Treatment for Adult Cancer Patients

Year: 2016
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adults (aged 18 and older) at any phase of the cancer care continuum regardless of cancer type, stage (including metastatic) or treatment plan, with some components of the guideline also applicable to the patient's family and/or caregivers. Recommendations are provided on implementation of the brief tobacco intervention using the evidence-based AAR Brief Tobacco Intervention Model which includes screening, education and assessment, treatment plan, and referral, monitoring, and follow-up. The 2015 guideline was revised in June 2016 to abbreviate the cessation intervention model to best support adoption across all CCA clinics and settings. Clinical considerations and contraindications of treatment options for cancer patients are discussed including nicotine replace therapy (NRT), bupropion, varenicline, and e-cigarettes, and the impact of tobacco use on cancer treatment is reviewed with a specific focus on erlotinib and irinotecan.

Stem Cell Transplantation in the Treatment of Acute Lymphoblastic Leukemia

Year: 2016
AGREE II score: Disponible
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for stem cell transplantation (SCT) in the treatment of acute lymphoblastic leukemia. The guideline establishes indications for allogeneic stem cell transplantation (allo-SCT) in the management of acute lymphoblastic leukemia (ALL) in adults. It identifies the role of reduced-intensity conditioning (RIC) regimens for SCT in the management of ALL adult patients, and the role of tyrosine-kinase inhibitors (TKIs) for patients undergoing allo-SCT for Philadelphia chromosome-positive ALL (Ph+ ALL). The guideline also discusses the role of alternative donor transplantation (haploidentical, cord blood) in the management of adult patients with ALL who lack a suitable donor. Outcomes of interest are relapse, disease-free survival, relapse-free survival, progression-free survival, and overall survival.

Soft Tissue Sarcoma – Version 1.2017

Year: 2016
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for soft tissue sarcoma. The guideline examines diagnosis, treatment and follow up. Various stages are addressed, as well as a various treatment options and disease progression. Guidance is presented for specific issues (e.g., gastrointestinal stromal tumors).

ACR Appropriateness Criteria Non-Spine Bone Metastases

Year: 2015
AGREE II score: Disponible
Developer organization: American College of Radiology
This is a clinical practice guideline for cancer patients with non-spine bone metastases. The guideline examines treatment options for these patients, which include radiotherapy, systemic therapies, and surgical stabilization, and the appropriateness of different techniques is examined for different clinical situations. Outcomes of interest include reductions in pain, and improved palliative care.

Imatinib Mesylate (Gleevec™) for the Treatment of Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumours

Year: 2015
AGREE II score: Disponible
Developer organization: Cancer Care Ontario
This clinical practice guideline reviews the use of imatinib in the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) expressing KIT (CD117+). Recommendations are provided on dosage and schedule. Outcomes of interest include overall and progression free survival, and quality of life.

Suspected Cancer: Recognition and Referral

Year: 2015
AGREE II score: Disponible
Developer organization: National Institute for Health and Care Excellence
This is a clinical practice guideline for patients of all age groups suspected of having cancers including lung and pleural, upper gastro-intestinal, lower gastrointestinal, breast, gynecological, urological, skin, head and neck, brain and central nervous system, haematological, sarcomas, and childhood cancers. Recommendations are provided on recognition and referral or investigations of cancer in primary care. Outcomes of interest include quality of life, sensitivity and specificity of diagnostic tests and signs/symptoms, positive and negative predictive values of diagnostic tests and signs/symptoms, and cost effectiveness.

Bone Cancer, Version1.2016

Year: 2015
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline reviews workup and treatment of bone cancer, with specific recommendations provided for chondrosarcoma, chordoma, Ewing's sarcoma family of tumours, and osteosarcoma. Surveillance and relapse are also reviewed. An overview of systemic therapy agents is provided, and principles of radiation therapy are discussed.

Oncogenetic Testing and Follow-up for Women With Familial Breast/Ovarian Cancer, Li-Fraumeni Syndrome and Cowden Syndrome

Year: 2015
AGREE II score: Disponible
Developer organization: Belgian Health Care Knowledge Centre
This is a clinical practice guideline for adult women (18 years and older) either without breast cancer or with a recent diagnosis of breast cancer, who have a family history of breast, ovarian or a related cancer; the guideline also provides recommendations for men affected by male breast cancer. The guideline discusses oncogenetic testing aspects of breast cancer and ovarian, specifically hereditary breast cancer, the Li-Fraumeni syndrome, and the Cowden syndrome. Topics include criteria and indications for genetic testing, tests for which genes have clinical utility, and appropriate follow-up depending on results and family history.

ACR Appropriateness Criteria Follow-up of Malignant or Aggressive Musculoskeletal Tumors

Year: 2015
AGREE II score: Disponible
Developer organization: American College of Radiology
This is a clinical practice guideline for the follow up of malignant or aggressive musculoskeletal tumours. The guideline discusses the timing of surveillance and the type of imaging used, with a focus on FDG-PET/CT and MRI, as well as ultrasound, X-ray, and Tc-99m bone scan. Sensitivity, specificity, recurrence rate, and survival (overall and progression-free) are all considered as outcomes.

ACR Appropriateness Criteria Metastatic Epidural Spinal Cord Compression and Recurrent Spinal Metastasis

Year: 2015
AGREE II score: Disponible
Developer organization: American College of Radiology
This is a clinical practice guideline for patients with recurrent spinal metastasis resulting in metastatic epidural spinal cord compression. The guideline examines the appropriateness of various treatment options including systemic therapy, surgical intervention, radiation therapy, osteoclast inhibitors and hospice care. The appropriateness of different techniques for unique clinical situations is discussed. Outcomes of interest include neurologic status, performance status, extent of disease, spine stability and life expectancy.

Tobacco Screening And Treatment For Adult Cancer Patients

Year: 2015
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adults (aged 18 and older) at any phase of the cancer care continuum regardless of cancer type, stage (including metastatic) or treatment plan, with some components of the guideline also applicable to the patient's family and/or caregivers. The guideline provides recommendations on implementation of the brief tobacco intervention, using the evidence-based 5 A’s model (ASK, ADVISE, ASSESS, ASSIST, ARRANGE) which includes screening, education and assessment, treatment plan, and referral, monitoring, and follow-up. Clinical considerations and contraindications of treatment options for cancer patients are discussed including nicotine replace therapy (NRT), bupropion, varenicline, and e-cigarettes. The impact of tobacco use on cancer treatment is also reviewed with a specific focus on erlotinib and irinotecan.

Treatment Guidelines for Preoperative Radiation Therapy for Retroperitoneal Sarcoma: Preliminary Consensus of an International Expert Panel

Year: 2015
AGREE II score: Unavailable
Developer organization: National Cancer Institute
An international panel of radiation oncologists who specialize in sarcoma reached consensus guidelines for preoperative radiation therapy (RT) for retroperitoneal sarcoma (RPS). Many of the recommendations are based on expert opinion because of the absence of higher level evidence and thus, are best regarded as preliminary. At the time of publication, the guideline developers were awaiting data from the European Organization for Research and Treatment of Cancer (EORTC) study of pre- operative radiotherapy plus surgery versus surgery alone for patients with RPS. Further data are also anticipated pertaining to normal tissue dose constraints, particularly for bowel tolerance. Nonetheless, the guidelines can be used to establish treatment uniformity to aid future assessments of efficacy and toxicity.

Required Reports for Referrals

Year: 2014
AGREE II score: Unavailable
Developer organization: BC Cancer Agency
This guideline set provides recommendations on required reports for referrals for: breast, gastrointestinal (esophagus, stomach, colon-rectum, anus, pancreas, liver, biliary tract/gall bladder), genitourinary (testis, prostate, bladder), gynecology (endometrium, cervix, ovary, vulva & vagina), head and neck (parotid & submandibular gland, thyroid, mouth, palate, nasopharynx, oropharynx, hypopharynx, nose & antrum, ear), lung, lymphoma and leukemia, melanoma, musculoskeletal and sarcoma, neuro-oncology, primary unknown, and skin (basal cell & squamous cell carcinomas, mycosis fungoides – Sezary syndrome). The guideline provides recommendations on pathology reports, operative reports, laboratory reports, and imaging reports. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

Musculoskeletal & Sarcoma Cancer

Year: 2014
AGREE II score: Unavailable
Developer organization: BC Cancer Agency
This guideline set provides recommendations on the management of musculoskeletal cancers including bone cancer and soft tissue sarcoma. Topics of discussion include prevention, diagnosis and staging, management, and follow-up. Additionally, diagnostic pathology, and treatment through chemotherapy, radiotherapy, and surgery are discussed. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

Clinical Practice Guidelines for the Management of Adult Onset Sarcoma

Year: 2014
AGREE II score: Disponible
Developer organization: Cancer Council Australia
This is a clinical practice guideline for adults suspected of having or diagnosed with adult onset sarcoma. The guideline provides recommendations on diagnosis and staging, treatment, and follow-up care. Chemotherapy, radiotherapy, and surgery are discussed as treatment options. Outcomes of interest include local recurrence, survival (overall, long term), and quality of life.

Soft Tissue and Visceral Sarcomas: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up

Year: 2014
AGREE II score: Unavailable
Developer organization: European Society for Medical Oncology
This is a clinical practice guideline for adults diagnosed with or suspected of having soft tissue or visceral sarcoma. The guideline discusses diagnosis, staging and risk assessment, and treatment stratified by whether disease type is localized or advanced. Follow-up care is also reviewed. Treatment options for patients with special presentations and entities is also discussed, including patients with retroperitoneal sarcomas, uterine sarcomas, desmoid-type fibromatosis, and breast sarcomas.

Early Detection of Cancer in AYAs

Year: 2014
AGREE II score: Disponible
Developer organization: Cancer Council Australia
This is a clinical practice guideline for the early detection of common cancers in adolescents and young adults aged between 15 and 24 years of age. The cancers covered include leukemia, lymphoma, brain tumours, soft tissue sarcoma, testicular cancer, thyroid cancer, and melanoma. The guideline discusses common signs and symptoms and provides recommendations on clinical assessment and referral. "Youth-friendly" communication between practitioner and patient is also discussed, and links for patient and practitioner resources are provided.

British HIV Association Guidelines for HIV-Associated Malignancies 2014

Year: 2014
AGREE II score: Disponible
Developer organization: British HIV Association
This is a clinical practice guideline for the diagnosis and treatment of cancer and associated malignancies in adult patients with HIV. The guideline examines the most common HIV associated cancers, Kaposi sarcoma, high grade B-cell non-Hodgkin lymphoma and invasive cervical cancer, as well as a number of other cancers with higher risk profiles in HIV patients. Outcomes of interest include improved treatment options in consideration of HAART and increased prophylactic options in low-risk patients, specifically with regards to lifestyle changes and vaccinations.

Follow-Up Surveillance of Soft Tissue Sarcoma

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for patients who have undergone treatment for soft tissue sarcomas. The guideline examines appropriate surveillance and follow up methods, including regular imaging and physical examination. Outcomes of interest include preference for x-rays over MRI or CT, and increased postoperative imaging.

Proton Beam Radiation Therapy

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This clinical practice guideline reviews the use of proton beam radiation therapy to treat cancers in pediatric, adolescent, and adult patients. The guideline examines the benefits of proton beam radiation therapy for different cancer types, and discusses the referral and funding process for out-of-country treatment. Outcomes of interest include local control, survival (progression-free and overall), acute and late toxicities, and recurrence rates.

Liposomal Anthracyclines in the Management of Patients with HIV-Positive Kaposi’s Sarcoma

Year: 2013
AGREE II score: Disponible
Developer organization: Cancer Care Ontario
A clinical practice guideline for patients with HIV-positive Kaposi’s sarcoma. The guideline examines the use of liposomal anthracycline therapy in aggressive cutaneous or visceral disease sites and comparisons are made to combination chemotherapy. Outcomes of interest include no significant differences between liposomal therapy and conventional combination therapy.

Optimal Treatment Options and Follow-up Strategies in Patients with Desmoid Tumours

Year: 2013
AGREE II score: Unavailable
Developer organization: Cancer Care Ontario
A clinical practice guideline for patients with desmoid tumours who are either pursuing active treatment or have already received primary treatment. The guideline examines treatment and follow-up strategies, including recommendations for multiple concurrent treatment options and appropriate rehabilitation. Outcomes of interest include lack of statistically significant information for optimal treatment choice, and increased focus on multidisciplinary sarcoma teams.

Provincial Myelodysplastic Syndrome Treatment Guidelines

Year: 2012
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for the diagnosis and treatment of patients with myelodysplastic syndrome. The guideline examines the presentation of myelodysplastic syndrome in older and elderly patients, and treatment options for lower and higher risk patients. Outcomes of interest include improved quality of life, including prolonged survival, and improved blood cytopenia.

Appropriate Surgical Margins and Proper Handling of Soft Tissue Sarcoma of the Extremities

Year: 2012
AGREE II score: Disponible
Developer organization: Cancer Care Ontario
This clinical practice guideline discusses limb-sparing surgery as a treatment for eligible patients with soft tissue sarcoma of the extremities. Adequate margins, appropriate number of surgical resection specimens, and appropriate handling techniques of specimens are examined. The appropriate use of pre- and post-operative radiotherapy is also discussed. Outcomes of interest include recurrent free survival and overall survival.

SIE, SIES, GITMO Evidence-Based Guidelines on Novel Agents (Thalidomide, Bortezomib, and Lenalidomide) in the Treatment of Multiple Myeloma.

Year: 2012
AGREE II score: Disponible
Developer organization: Italian Society of Hematology
A clinical practice guideline for patients with multiple myeloma. The guideline examines the use of thalidomide, bortezomib, and lenalidomide regimens with relation to autologous stem cell transplantation, and includes maintenance therapy recommendations. Risk factors such as age are also considered.

Bone Sarcomas: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up

Year: 2012
AGREE II score: Unavailable
Developer organization: European Society for Medical Oncology
This clinical practice guideline is for cancer patients who are being considered for anti-TNF-alpha therapy. Treatment related infections are reviewed, including tuberculosis, human papilloma virus, hepatitis B and C, Varicella zoster virus, Herpes simplex virus, cytomegalovirus, Epstein Barr virus and human immunodeficiency virus. The guideline discusses risk factors for developing infection, and provides recommendations on preventative measures such as vaccination for at-risk individuals.

Soft Tissue and Visceral Sarcomas: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up

Year: 2012
AGREE II score: Unavailable
Developer organization: European Society for Medical Oncology
A clinical practice guideline for the management of patients with soft tissue and visceral sarcomas. The guideline examines surgical intervention with systemic therapies, following diagnosis and staging through imaging and core needle biopsies. Considerations include risk of relapse and differences in treatment for special presentations.

Bone Sarcomas: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up

Year: 2012
AGREE II score: Unavailable
Developer organization: European Society for Medical Oncology
This is a clinical practice guideline for the management of bone sarcomas including osteosarcoma, Ewing sarcoma, high-grade spindle/pleomorphic sarcomas of bone, chondrosarcoma, giant cell tumour of bone, and chordoma. The guideline provides recommendations on diagnostic assessment and staging, treatment, and follow-up care. Outcomes of interest include incidence of subtypes, local recurrence, and survival.

Chemotherapy (i.e., Gemcitabine, Docetaxel Plus Gemcitabine, Doxorubicin, or Trabectedin) for Inoperable, Locally Advanced, Recurrent, or Metastatic Uterine Leiomyosarcoma

Year: 2012
AGREE II score: Disponible
Developer organization: Cancer Care Ontario
This clinical practice guideline discusses the use of chemotherapy for the treatment of locally advanced, recurrent, or metastatic uterine leiomyosarcoma (LMS) in adult women. Gemcitabine, docetaxel plus gemcitabine, doxorubicin, and trabectedin are compared, and the use of granulocyte growth factor (G-CSF) is considered. Outcomes of interest include overall and progression-free survival time, tumour response rate, stable disease rate, progressive disease rate, and toxicity.

Appropriate Surgical Margins and Proper Handling of Soft Tissue Sarcoma of the Extremities

Year: 2012
AGREE II score: Disponible
Developer organization: Cancer Care Ontario
A clinical practice guideline for patients with soft tissue sarcoma of the extremities and who are candidates for limb-sparing surgery. The guideline examines surgical margins for limb salvage surgery and margins for surgery in combination with chemotherapy and/or radiation. Outcomes of interest include clearer surgical margins and improved radiation treatment margins.